Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses potential links between early-onset androgenetic alopecia and exposure to endocrine disruptors in adolescents, but reports no clinical results; the authors suggest further investigation.

This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.

In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.

This article highlights that permanent chemotherapy-induced alopecia can occur and is more commonly associated with taxane therapy, advising awareness among patients and clinicians.

Possible endocrine disorders caused woman's hair loss and obesity in painting.

This review posits that alopecia in PCOS results from the interaction between local follicular signaling failures, insulin resistance, inflammation, and genetic predispositions, rather than solely from androgen excess, and recommends a systems-level framework for its management.

This study found that in female androgenetic alopecia, androgen receptors are highly positive in affected areas, supporting their role as regulators of genetically predisposed hair follicles despite normal serum hormone levels.

This abstract provided no research findings as it contains only website navigation and service information.

An integrative approach combining medical, nutritional, and lifestyle changes effectively manages female pattern hair loss.

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.

This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

This chapter reviews the clinical features, diagnosis, treatment, and prognosis of various non-hormonal, non-infectious alopecias without providing new clinical findings.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This review discusses various causes and patterns of canine alopecia, noting that symmetrical and diffuse hair loss often indicates an endocrinopathy, and reports no new clinical results.

This paper proposes a new hypothesis that androgenic hair loss may be caused by changes in scalp vasculature due to androgen effects, but reports no new experimental results.

This article discusses the diagnostic approach to symmetrical alopecia in dogs, particularly focusing on conditions affecting the endocrine glands and hair follicles, without presenting new research results.

This article reviews current evaluation and treatment options for androgenic alopecia in women and reports no new clinical results.

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This study assesses the impact of teaching programs on the knowledge of waste management among women, but results are not reported in the abstract.

In this review, the authors highlight that drugs promoting androgenic activity or inhibiting estrogenic activity may unmask or worsen androgenetic alopecia in genetically predisposed individuals, indicating the need for careful management in clinical settings.

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.

Recent hair loss research shows some progress, especially in understanding male pattern baldness, but effective treatments for many types of hair loss are still lacking.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.